New Vaccine Improves Survival Among Patients with Melanoma
Source: CureToday, April 2024
A vaccine developer discusses a cancer vaccine that has been shown to potentially boost long-term overall postsurgical survival.
A new melanoma vaccine has been shown to improve long-term survival among patients when compared to prior iterations of the vaccine, according to recently published research.
Among patients with stages 2B to 4 surgically removed melanoma, the vaccine, developed at UVA Cancer Center, resulted in overall survival (the time a patient lives following treatment) of 74%, 68% and 61% at five, 10 and 15 years, compared with 68%, 56% and 45%, respectively, for the prior version of the vaccine, according to findings published in the journal Nature Communications. Researchers also found that these improved results were also clearer among male patients.